초록접수 현황
| 20F-021 | 구연 발표 |
Clinical Course of Asymptomatic Malignant Pleural Effusion in Non-Small Cell Lung Cancer Patients: A Multicenter Retrospective Study
Hyo Yeong Ahn1, Jeong Su Cho1, Hoseok I1, Yeong Dae Kim1,Jiyeon Roh2, Insu Kim3, Ju Hyeong Son4, Hee Yun Seol5, Jung Seop Eom2
1Department of Thoracic and Cardiovascular Surgery, Pusan National University School of Medicine, Busan, Republic of Korea
2Department of Intermal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea
3Department of Internal Medicine, Dong-A University Hospital, Busan, Republic of Korea
4Department of Thoracic and Cardiovascular Surgery, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
5Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea
Purpose : The British Thoracic Society guidelines recommend observation for patients with asymptomatic malignant pleural effusion (MPE). However, asymptomatic MPE can become symptomatic. This study examined the clinical course of asymptomatic MPE in patients with non-small cell lung cancer (NSCLC), including the incidence and timing of symptom development of asymptomatic MPE and the associated factors.
Methods : Retrospective data of 4822 NSCLC patients between January 2012 and December 2017 were reviewed. Symptom development of asymptomatic MPE was defined as the development of symptoms requiring additional treatment, such as insertion of a chest tube, within 1 year in patients who lacked MPE symptoms at the time of diagnosis. Clinical information, pathological parameters, and radiological characteristics were reviewed. Patient data up to 1 year from the initial diagnosis were reviewed.
Results : Of 113 patients with asymptomatic MPE, 46 (41%) became symptomatic within 1 year despite appropriate anticancer treatment. The median time to symptom development was 4 months, and 38 patients (83%) developed symptoms within 6 months. Multivariate logistic regression showed that female gender [odds ratio (OR), 0.256; 95% confidence interval (CI), 0.101–0.649; P = 0.004] and the depth of pleural effusion on initial CT (OR, 0.957; 95% CI, 0.932–0.982; P = 0.001) were independently associated with symptom development of asymptomatic MPE.
Conclusion : A fraction of 41% of patients with asymptomatic MPE became symptomatic within 1 year. Female gender and larger MPE on initial CT were independently associated with symptom development of asymptomatic MPE.
Methods : Retrospective data of 4822 NSCLC patients between January 2012 and December 2017 were reviewed. Symptom development of asymptomatic MPE was defined as the development of symptoms requiring additional treatment, such as insertion of a chest tube, within 1 year in patients who lacked MPE symptoms at the time of diagnosis. Clinical information, pathological parameters, and radiological characteristics were reviewed. Patient data up to 1 year from the initial diagnosis were reviewed.
Results : Of 113 patients with asymptomatic MPE, 46 (41%) became symptomatic within 1 year despite appropriate anticancer treatment. The median time to symptom development was 4 months, and 38 patients (83%) developed symptoms within 6 months. Multivariate logistic regression showed that female gender [odds ratio (OR), 0.256; 95% confidence interval (CI), 0.101–0.649; P = 0.004] and the depth of pleural effusion on initial CT (OR, 0.957; 95% CI, 0.932–0.982; P = 0.001) were independently associated with symptom development of asymptomatic MPE.
Conclusion : A fraction of 41% of patients with asymptomatic MPE became symptomatic within 1 year. Female gender and larger MPE on initial CT were independently associated with symptom development of asymptomatic MPE.
첨부파일 : Manuscript_ERJ(table).docx
책임저자: Jung Seop Eom
Department of Intermal Medicine, Pusan National University School of Medicine, Busan, Republic of Korea
발표자: Hyo Yeong Ahn, E-mail : doctorahn02@hanmail.net